Eton Pharmaceuticals, Inc. (NASDAQ:ETON) is one of the best oversold growth stocks to invest in now. H.C. Wainwright lifted the price target on Eton Pharmaceuticals, Inc. (NASDAQ:ETON) to $57 from $52 on May 15, reaffirming a Buy rating on the shares and citing the company’s elevated fiscal 2026 revenue guidance and confidence in its growth strategy for the target bump. The firm further told investors in a research note that the company’s stated long-term goals could be achievable, given its execution to date.
The rating update came after Eton Pharmaceuticals, Inc. (NASDAQ:ETON) reported its fiscal Q1 2026 results on May 14, reporting product sales of $24.3 million for the quarter, reflecting a 73% growth over Q1 2025. It also raised its full-year revenue guidance, and now anticipates 2026 revenue to surpass $120 million, up from previous guidance of $110 million. The company further reported that fiscal Q1 2026 fully diluted GAAP EPS was $0.05, non-GAAP fully diluted EPS was $0.14, and adjusted EBITDA reached $5.7 million. Eton Pharmaceuticals, Inc. (NASDAQ:ETON) also received FDA approval for and launched DESMODA™, while also acquiring and relaunching HEMANGEOL®.
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) is a pharmaceutical company that develops and sells treatments for rare diseases. The company focuses on bringing therapies to patients with limited treatment options.
While we acknowledge the potential of ETON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey on Google News.
Leave a comment